

Dr Matthew Armstrong MBChB (Hons) BSc (Hons) MRCP

Wellcome Trust Clinical Research Fellow and Honorary SpR in Hepatology

School of Immunity and Infection

Contact details

Telephone **+44 (0)121 415 8700 (tel:+44 121 415 8700)**

Telephone (2) **+44 (0)7968470622 (tel:+44 7968470622)**

Email **armstrom@bham.ac.uk (mailto:armstrom@bham.ac.uk)**

School of Immunity and Infection
Centre for Liver Research
5th Floor of Institute of Biomedical Research
College of Medical and Dental Sciences
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK



About

Dr Matthew Armstrong is a Wellcome Trust Clinical Research Fellow (commenced Oct 2009). He qualified from Leeds Medical School in 2004 with honours, during which he obtained a 1st Class BSc in clinical sciences with research in small bowel surgery. His post-graduate training was undertaken in hospitals throughout the Yorkshire region, until he started his PhD at Birmingham University in 2009.

His keen interests lie in non-alcoholic fatty liver disease (NAFLD). His translation research involves a multicentre trial looking into the efficacy and mechanisms of a new group of diabetes drugs in NAFLD patients. He is a keen teacher.

Qualifications

- Member of the Royal College of Physicians 2007
- MBChB (hons) 2004
- BSc Clinical Science (Hons) 2002

Research

RESEARCH THEMES

Non-alcoholic fatty liver disease, non-invasive markers, liver function tests, Glucagon-like peptide 1 analogues.

RESEARCH ACTIVITY

NAFLD + GLP-1 analogues

Ongoing PhD studies involving Phase II Randomised Placebo-controlled Multi-centre Trial in NAFLD, including 2-step hyperinsulinaemic euglycaemic clamp and adipose microdialysis. In-vitro cell work looking at the direct effects of GLP-1 (receptor dependent vs non-dependent) on human hepatocytes and cell-lines.

Since 2009 he has presented his work at international liver and diabetes conferences.

Other activities

- Honorary SpR in Hepatology at QE UHB
- STC Trainee representative for Yorkshire Deanery Gastroenterology Training

Publications

Armstrong MJ, Houlihan DD, Bentham L, et al. Presence and Severity of Nonalcoholic Fatty Liver Disease in a Large, Prospective Primary Care Cohort. *J Hepatol* 2011 (accepted Mar 2011; in press)

Dowman JD, Armstrong MJ, Tomlinson JW, Newsome PN. Current Therapeutic Strategies in Nonalcoholic Fatty Liver Disease (NAFLD). *Diabetes Obes Metab* 2011 (accepted Mar 2011; in press)

Hegade VS, Armstrong MJ, Smithson JA. Hepatic Schistosomiasis. *QJM* Nov 2010. [Epub ahead of print]

Armstrong MJ, Houlihan DD, Rowe IA. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *N Engl J Med*. 2010 Sep 16;363(12):1185; author reply 1186.

Armstrong MJ, Robins GG, Howdle PD. **Recent advances in coeliac disease.** (<http://www.ncbi.nlm.nih.gov/pubmed/19528877>) *Curr Opin Gastroenterol*. 2009;25(2):100-9. Review.

Armstrong MJ, Booth C. **Electronic health records in ambulatory care.** (<http://www.ncbi.nlm.nih.gov/pubmed/18946074>) *N Engl J Med*. 2008 Oct 23;359(17):1848; author reply 1849.

Robins GG, Sarwar MS, Armstrong MJ, et al. Evaluation of the need for endoscopy to identify low-risk patients presenting with an acute upper gastrointestinal bleed suitable for early discharge. *Postgrad Med J*. 2007 Dec;83(986):768-72.

Williams L, Armstrong MJ, Finan P, et al. [The effect of faecal diversion on human ileum. \(http://www.ncbi.nlm.nih.gov/pubmed/17229794\)](http://www.ncbi.nlm.nih.gov/pubmed/17229794) *Gut*. 2007 Jun;56(6):796-801.

[Privacy](#) | [Legal](#) | [Cookies and cookie policy](#) | [Accessibility](#) | [Site map](#) | [Website feedback](#) | [Charitable information](#)

© University of Birmingham 2015

